4.6 Article

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

Related references

Note: Only part of the references are listed.
Editorial Material Immunology

Interleukin 17-A inhibition in the treatment of psoriasis

Zenas Z. N. Yiu et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)

Article Medicine, General & Internal

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

K. B. Gordon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Review Cell Biology

Resident memory T cells in human health and disease

Rachael A. Clark

SCIENCE TRANSLATIONAL MEDICINE (2015)

Review Dermatology

PASI90 response: the new standard in therapeutic efficacy for psoriasis

L. Puig

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)

Review Microbiology

Interleukin 17-Mediated Host Defense against Candida albicans

Florian Sparber et al.

PATHOGENS (2015)

Review Immunology

Immunology of Psoriasis

Michelle A. Lowes et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)

Article Medicine, Research & Experimental

Psoriasis

Paola Di Meglio et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)

Review Dermatology

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Rosa Parisi et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)

Review Biotechnology & Applied Microbiology

Targeting IL-17and TH17 cells in chronic inflammation

Pierre Miossec et al.

NATURE REVIEWS DRUG DISCOVERY (2012)

Article Immunology

Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

Vinod Chandran et al.

JOURNAL OF AUTOIMMUNITY (2010)

Review Medicine, General & Internal

Mechanisms of Disease: Psoriasis.

Frank O. Nestle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Biotechnology & Applied Microbiology

Biologics for psoriasis

DB Dubin et al.

NATURE REVIEWS DRUG DISCOVERY (2003)